Dave Fellows, Beacon Therapeutics CEO

Ex-Night­star, Gy­ro­scope and AGTC teams try again for next reti­nal gene ther­a­py with $120M for Bea­con Ther­a­peu­tics

Life sci­ences in­vestor Syn­cona is tak­ing a sec­ond shot at X-linked re­tini­tis pig­men­tosa, this time with Bea­con Ther­a­peu­tics, a reti­nal gene ther­a­py start­up led by …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.